These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30560246)

  • 21. The Rules of Engagement: Do Microglia Seal the Fate in the Inverse Relation of Glioma and Alzheimer's Disease?
    Cheray M; Stratoulias V; Joseph B; Grabert K
    Front Cell Neurosci; 2019; 13():522. PubMed ID: 31824268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allergy may confer better survival on patients with gliomas.
    Lehrer S; Rheinstein PH; Rosenzweig KE
    Clin Neurol Neurosurg; 2019 Feb; 177():63-67. PubMed ID: 30611004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is mortality due to primary malignant brain and other central nervous system tumors decreasing?
    Gittleman H; Kromer C; Ostrom QT; Blanda R; Russell J; Kruchko C; Barnholtz-Sloan JS
    J Neurooncol; 2017 Jun; 133(2):265-275. PubMed ID: 28470430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High CHI3L1 expression is associated with glioma patient survival.
    Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
    Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma.
    Sampath P; Weaver CE; Sungarian A; Cortez S; Alderson L; Stopa EG
    Cancer Control; 2004; 11(3):174-80. PubMed ID: 15153841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor diagnosis preceding Alzheimer's disease onset: is there a link between cancer and Alzheimer's disease?
    Realmuto S; Cinturino A; Arnao V; Mazzola MA; Cupidi C; Aridon P; Ragonese P; Savettieri G; D'Amelio M
    J Alzheimers Dis; 2012; 31(1):177-82. PubMed ID: 22531415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Zhang AS; Ostrom QT; Kruchko C; Rogers L; Peereboom DM; Barnholtz-Sloan JS
    Neuro Oncol; 2017 May; 19(5):726-735. PubMed ID: 28039365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marital Status Independently Predicts Glioma Patient Mortality: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Deng Z; Li X; Yang J; Yu H; Zhang N
    World Neurosurg; 2021 Aug; 152():e302-e312. PubMed ID: 34058360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An independently validated survival nomogram for lower-grade glioma.
    Gittleman H; Sloan AE; Barnholtz-Sloan JS
    Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
    Gressot LV; Doucette T; Yang Y; Fuller GN; Manyam G; Rao A; Latha K; Rao G
    Oncotarget; 2017 Feb; 8(8):12695-12704. PubMed ID: 27074575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis.
    Alattar AA; Brandel MG; Hirshman BR; Dong X; Carroll KT; Ali MA; Carter BS; Chen CC
    J Neurosurg; 2018 Apr; 128(4):1076-1083. PubMed ID: 28498059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival.
    Ostrom QT; Gittleman H; Kruchko C; Barnholtz-Sloan JS
    J Neurooncol; 2019 Mar; 142(1):27-38. PubMed ID: 30543034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups.
    Lin W; Wu S; Chen X; Ye Y; Weng Y; Pan Y; Chen Z; Chen L; Qiu X; Qiu S
    Front Oncol; 2020; 10():796. PubMed ID: 32500034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
    Ius T; Ciani Y; Ruaro ME; Isola M; Sorrentino M; Bulfoni M; Candotti V; Correcig C; Bourkoula E; Manini I; Pegolo E; Mangoni D; Marzinotto S; Radovic S; Toffoletto B; Caponnetto F; Zanello A; Mariuzzi L; Di Loreto C; Beltrami AP; Piazza S; Skrap M; Cesselli D
    Neuro Oncol; 2018 May; 20(6):776-787. PubMed ID: 29228370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013.
    Walker EV; Davis FG;
    Neuro Oncol; 2019 Feb; 21(3):360-369. PubMed ID: 30649461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis.
    Mikkelsen T; Yan PS; Ho KL; Sameni M; Sloane BF; Rosenblum ML
    J Neurosurg; 1995 Aug; 83(2):285-90. PubMed ID: 7542317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.